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unfolded	 protein	 response	 (UPR)	 that	 matches	 ER	 chaperone	 capacity	 to	 the	
burden	of	unfolded	proteins.	As	levels	of	unfolded	proteins	decline,	a	metazoan-
specific	 FIC-domain	 containing	 ER-localized	 enzyme,	 FICD	 (HYPE),	 rapidly	
inactivates	the	major	ER	chaperone	BiP	by	AMPylating T518.	Here	we	show	that	
the	single	catalytic	domain	of	FICD can	also	release	the	attached	AMP,	restoring	
functionality	 to	 BiP.	 Consistent	 with	 a	 role	 for	 endogenous	 FICD	 in	de-
AMPylating	 BiP,	 FICD
-/-
hamster cells	 are	 hypersensitive	 to	 introduction	 of	 a	
constitutively	 AMPylating,	 de-AMPylation	 defective	 mutant	 FICD.	 These
opposing	 activities	 hinge	 on	 a	 regulatory	 residue,	 E234,	 whose	 default	 state	
renders	 FICD	 a	 constitutive	 de-AMPylase	 in	 vitro.	 The	 location	 of	 E234	 on	 a	
conserved	 regulatory	 helix	 and	 the	 mutually	 antagonistic	 activities	 of	 FICD	 in	




































































































































































































































































































































, at similar levels to wildtype FICD, had	no	effect	
on	UPR	signaling,	suggesting an insignificant increase in the unfolded protein load 
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Immunoblot	 of	 endogenous	 BiP	 resolved	 by	 native	 gel	 electrophoresis	 from	
wildtype	 (wt)	 and	 FICD	deficient	 (-/-)	 CHO-K1	 cells	 transfected	with	 plasmids	
encoding	the	indicated	FICD	derivatives	and	exposed	to	cycloheximide	(CHX)	to	
promote	AMPylated	BiP.	The	major	 species	of	 BiP	 oligomers	 are	 numbered	 by	
order	of	descending	mobility	(I-III).	The	monomeric	AMPylated	‘B’	form	induced	
by	 CHX	 treatment	 and	 the	 ‘A’	 form	 detectable	 in	 untreated	 cells	 are	 marked.	
Immunoblots	of	 the	same	samples	resolved	by	SDS-PAGE	report	on	FICD,	 total	
BiP	 and	 total	 eIF2a	 (which	 also	 serves	 as	 a	 loading	 control)	 and	 the	 acidic	
AMPylated	‘B’	form	of	BiP	resolved	by	isoelectric	focusing	gel	(IEF).	The	asterisk	


































FICD-mediated	 de-AMPylation	 releases	 AMP	 and	 restores	 BiP	 to	 its	pre-
AMPylation	state	
(a)	LC-MS	spectra	of	 peptides	 from	 an	Arg-C	 digest	 of	 unmodified	BiP	 protein	


















elution	profile	of	known	standards	 (ATP,	ADP,	 and	AMP)	 are	 indicated	 in	 grey	
dotted	 lines.	 In	 the	 control	 reaction	 (black	 trace	 on	 the	 left	 panel)	 the	 FICD	
enzyme	was	 added	 to	 BiP-AMP	 followed	 immediately	 by	 deproteination.	FICD-
dependent	 appearance	 of	 an	 A254	 absorbance	 peak	 at	 the	 AMP-specific	 elution	
time	was	observed	in	three	independent	experiments.
(d)	CBB-stained	native-PAGE	gel	of	purified	in	vitro	AMPylated	BiP	that	had	been	





dimers	 (II),	 the	 AMPylated	 ‘B’	 form,	 and	 the	 nucleotide	 binding	 domain	 SubA	









(a)	Fluorograph	and	Coomassie	 stain	of	 intact	 or	 SubA	 cleaved	BiP	AMPylated	
with	 FAM-labeled	 AMP	 (BiP
T518-AMP-FAM




weight	fluorescent	 species	distinct	 from	 full-length	BiP
AMP-FAM
	 (FL)	 that	 is	not	a	
substrate	 for	 FICD-mediated	 de-AMPylation.	 A	 representative	 of	 two	
independent	experiments	is	shown.
(b)	 Time-dependent	 plot	 of	 fluorescence	 polarization	 (FP)	 measurement	 of	
BiP
T518-AMP-FAM



























of	 post-proteinaceous	 supernatants	 from	 samples	 derived	 from	 enzymatic	
reactions	incorporating	the	indicated	components.	In	the	control	reaction	(trace	
4,	green)	ATP	was	added	followed	immediately	by	deproteination.	Trace	5	and	6	
are	 of	 identical	 samples	 with	 the	 addition	 of	 AMP	 to	 trace	 6	 before	
chromatography	(orange).	Note	that	the	appearance	of	an	A254	absorbance	peak	












(a)	 Immunoblot	 of	 endogenous	 BiP	 from	 CHO-K1	 cells	 transfected	 with	 the	
indicated	 amount	 of	 plasmid	 DNA	 encoding	 wildtype	 FICD	 and	 exposed	 to	
cycloheximide	(CHX)	resolved	by	native-PAGE.	The	AMPylated	‘B’	form	of	BiP	is	
indicated	(as	are	the	other	major	species,	see	Fig.	1	legend).	Immunoblots	of	the	
same	samples	 resolved	by	SDS-PAGE	report	on	FICD,	 total	BiP	 and	 total	 eIF2α
(which	 also	 serves	 as	 a	 loading	 control).	 The	 asterisk	 indicates	 a	 background
band.	Data	representative	of	three	independent	experiments	are	shown.
(b)	Activity	of	 an	 integrated	CHOP::GFP	UPR	 reporter	 in	 isogenic	wildtype	 and	
FICD-deficient	CHO-K1	cells	 following	 transfection	with	 plasmids	 encoding	 the	
indicated	FICD	derivatives	and	an	mCherry	transfection	marker).	Shown	are	the	
median	values	±	SD	of	 the	GFP	 fluorescent	 signal	of	 the	mCherry-positive	 cells	





CHO-K1	 cells	 transduced	 with	 a	 puromycin	 resistance	 marked	 retrovirus














A	 hypothetical	 model	 depicting	 regulation	 of	 the	 FICD-mediated	 BiP	
AMPylation	and	de-AMPylation	cycle	by	the	disposition	of	E234
A	 cellular	 mechanism	 responsive	 to	 the	 changes	 in	 unfolded	 protein	 load	 is	
hypothesized	to	switch	FICD’s	function	by	altering	the	position	of	E234.
When	 unfolded	 proteins	 are	 scarce,	 active	 disengagement	 of	 FICD’s	 E234	
promotes	 the	 AMPylation-competent	 alignment	 of	 T518	 of	 BiP,	 ATP	 and	 key	
residues	 from	 the	 active	 site	 (H363	 and	 R374)	
16,17
,	 inactivating	 BiP.	 When	
unfolded	 proteins	 are	 abundant	 FICD	 returns	 to	 its	 default	 state.	 The	 engaged
E234	of	FICD	coordinates	a	water	molecule	 to	attack	 the	phosphodiester	bond	
between	 AMP	 and	 T518	 of	 BiP.	 The	 essential	 role	 of	 FICD’s	 H363	 in	de-
AMPylation	is	plausibly	attributed	to	protonation	of	the	BiP	T518	leaving	group.	
De-AMPylation	 returns	BiP	 to	 the	chaperone	cycle.	The	 bold	 arrows	 indicate	 a	
hypothesized	 movement	 of	 the	 regulatory	 α-helix	 harboring	 E234	 to	 switch	






All cells were grown on tissue culture dishes or multi-well plates (Corning) at 37°C 
and 5% CO2. CHO-K1 cells (ATCC CCL-61) were phenotypically validated as proline 
auxotrophs and their Cricitulus griseus origin was confirmed by genomic sequencing. 
The cells were cultured in Nutrient mixture F-12 Ham (Sigma) supplemented with 
10% (v/v) serum (FetalClone II; HyClone), 1 x Penicillin-Streptomycin (Sigma) and 2 
mM L-glutamine (Sigma). The CHO-K1 FICD-/- cell lines used in this study were 
described previously 12.
HEK293T cells (ATCC CRL-3216) were cultured in Dulbecco's Modified Eagle's 
Medium (Sigma) supplemented as described above.
Cell lines were subjected to random testing for mycoplasma contamination using the 
MycoAlert Mycoplasma Detection Kit (Lonza). Experiments were performed at cell 
densities of 60-90% confluence. Cells were treated with drugs at the following final 
concentrations: 100 µg/ml cycloheximide (Sigma), 2.5 µg/ml tunicamycin (Melford), 
0.5 µM thapsigargin (Calbiochem), and 6-8 µg/ml puromycin (Calbiochem). All drugs 
were first diluted in fresh, pre-warmed medium and then applied to the cells by 
medium exchange.
Detailed information on flow cytometry analysis procedures, and production of VSV-





Cell lysis was performed as described in 6 with modifications. In brief, mammalian cells 
were cultured on 10 cm dishes and treated as indicated and/or transfected using 
Lipofectamine LTX with 5 µg plasmid DNA unless	 indicated	 otherwise,	 and	
allowed	to	grow	for	24	hours. Before lysis the dishes were placed on ice, washed 
with ice-cold PBS, and cells were detached in PBS containing 1 mM EDTA using a 
cell scraper. The cells were sedimented for 5 minutes at 370 g at 4°C and lysed in HG 
lysis buffer [20 mM HEPES-KOH pH 7.4, 150 mM NaCl, 2 mM MgCl2, 10 mM D-
glucose, 10% (v/v) glycerol, 1% (v/v) Triton X-100] containing protease inhibitors (2 
mM PMSF, 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml aprotinin) with 100 U/ml 
hexokinase (from Saccharomyces cerevisiae Type F-300; Sigma) for 10 minutes on 
ice. The lysates were cleared for 10 minutes at 21,000 g at 4°C. BIO-RAD protein 
assay reagent (BioRad) was used to determine the protein concentrations of lysates 
followed by normalization. For analysis by SDS-PAGE, SDS sample buffer was added 
to the lysates and proteins were denatured by heating for 10 minutes at 70°C before 
separation on 12.5% SDS polyacrylamide gels. To detect endogenous BiP by native-
PAGE the lysate samples were loaded immediately on native gels (see below). 
Plasmid construction
Supplementary Table 1 lists the plasmids used in this study. Standard PCR and 
molecular cloning methods were used to generate DNA constructs and point mutations 
were introduced by PCR-based site-directed mutagenesis.
Protein purification
N-terminally hexahistidine- (His6-) tagged wildtype and mutant Chinese hamster BiP 
proteins were expressed in M15 E. coli cells (Qiagen). The bacterial cultures were 
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grown at 37°C to an optical density (OD600 nm) of 0.8 in LB medium supplemented with 
50 µg/ml kanamycin and 100 µg/ml ampicillin and expression of recombinant protein 
was induced by the addition of 1 mM isopropylthio β-D-1-galactopyranoside (IPTG). 
The cells were further incubated at 37°C for 6 hours, harvested by centrifugation, and 
lysed with a high-pressure homogenizer (EmulsiFlex-C3, Avestin) in buffer A [50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 1 mM MgCl2, 0.2% (v/v) Triton X-100, 10% (v/v) 
glycerol, 20 mM imidazole] containing protease inhibitors [2 mM 
phenylmethylsulphonyl fluoride (PMSF), 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml 
aprotinin] and 0.1 mg/ml DNaseI. The obtained lysates were cleared by centrifugation 
for 30 minutes at 25,000 g and incubated with 1 ml Ni-NTA agarose (Qiagen) per 1 l 
of expression culture for 2 hours at 4°C. The matrix was transferred to a column and 
washed five times with 20 bed volumes of buffer A containing 5 mM β-
mercaptoethanol and supplemented sequentially with (i) 30 mM imidazole, (ii) 1% 
(v/v) Triton X-100, (iii) 1 M NaCl, (iv) 5 mM Mg2+-ATP, or (v) 0.5 M Tris-HCl pH 
7.5. Bound BiP proteins were eluted in buffer B [50 mM HEPES-KOH pH 7.5, 300 
mM NaCl, 10% (v/v) glycerol, 5 mM β-mercaptoethanol, 250 mM imidazole] and 
dialyzed against HKM buffer [50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM 
MgCl2]. The proteins were concentrated using centrifugal filters (Amicon Ultra, 30 
kDa MWCO; Merck Millipore), snap-frozen in liquid nitrogen, and stored at -80°C. 
Bacterial expression and purification of N-terminally GST-tagged wildtype and mutant 
FICD proteins was performed according to 12 with modifications. The FICD-encoding 
DNA constructs were transformed into C3013 BL21 T7 Express lysY/Iq E. coli cells 
(New England BioLabs) and cultures of single clones were grown at 37°C in LB 
medium containing 100 µg/ml ampicillin. At an OD600 nm of 0.8 the cultures were 
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shifted to 20°C and expression was induced with 0.5 mM IPTG. After incubation for 
16 hours the cells were harvested and lysed as described above in lysis buffer [50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 1 mM MgCl2, 2 mM dithiothreitol (DTT), 0.2% (v/v) 
Triton X-100, 10% (v/v) glycerol] containing protease inhibitors and DNaseI. The 
lysates were cleared by centrifugation for 30 minutes at 25,000 g and incubated with 
0.7 ml Glutathione Sepharose 4B (GE Healthcare) per 1 l of expression culture for 2 
hours at 4°C. The beads were washed with 20 ml wash buffer C [50 mM Tris-HCl pH 
7.5, 500 mM NaCl, 1 mM DTT, 0.2% (v/v) Triton X-100, 10% (v/v) glycerol] 
containing protease inhibitors, 20 ml wash buffer D [50 mM Tris-HCl pH 7.5, 300 mM 
NaCl, 10 mM MgCl2, 1 mM DTT, 0.1% (v/v) Triton X-100, 10% (v/v) glycerol] 
containing protease inhibitors and 20 ml wash buffer D sequentially supplemented with 
(i) 1% (v/v) Triton X-100, (ii) 1 M NaCl, (iii) 3 mM ATP, or (iv) 0.5 M Tris-HCl pH 
7.5. Bound proteins were eluted in elution buffer [50 mM HEPES-KOH pH 7.4, 100 
mM KCl, 4 mM MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100, 10% (v/v) glycerol, 40 
mM reduced glutathione] and concentrated protein solutions were frozen in liquid 
nitrogen and stored at -80°C. For preparation of wildtype FICD without the GST-tag 
the protein was eluted from glutathione-Sepharose in elution buffer without Triton X-
100 and with 1.5 mM DTT. TEV protease was added in a 100:1 (protein-to-TEV) 
molar ratio and after incubation for 16 hours at 4°C the proteins were passed over a 
size-exclusion chromatography column (Superdex 200 10/300 GL; GE Healthcare) in 
HKMG buffer [50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM MgCl2, 10% 
glycerol]. The FICD protein-containing fractions were pooled, concentrated, and 
frozen in aliquots. 
Purification of in vitro AMPylated BiP proteins
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AMPylated BiP proteins were prepared as described previously 12, with modifications. 
In brief, 20 mg of purified wildtype BiP or substrate-binding deficient BiPV461F mutant 
protein 31 was in vitro AMPylated for 4 hours at 30°C with 0.25 mg bacterially 
expressed FICDE234G in presence of 3 mM ATP in buffer E [25 mM HEPES-KOH pH 
7.4, 100 mM KCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100]. 
Afterwards, BiP proteins were bound to 400 µl Ni-NTA agarose affinity matrix for 30 
minutes at 25°C, washed with buffer E, and eluted in buffer E containing 350 mM 
imidazole for 45 minutes at 25°C. The eluate was concentrated and passed over a 
Centri•Pure P25 desalting column (emp BIOTECH) equilibrated in HKMG buffer. The 
protein-containing fractions were pooled, concentrated, frozen in liquid nitrogen, and 
stored at -80°C. BiP was quantitatively AMPylated as judged by the conversion of BiP 
oligomers into the modified monomeric ‘B’ form on a native-PAGE gel. The modified 
BiP proteins were used for in vitro de-AMPylation assays and mass spectrometry 
analysis (see below). Unmodified BiP prepared from a parallel mock AMPylation 
reaction without enzyme served as a control. 
In vitro AMPylation and de-AMPylation assays
Unless stated otherwise in vitro AMPylation and de-AMPylation reactions were 
performed in AMPylation buffer [25 mM HEPES-KOH pH 7.4, 100 mM KCl, 4 mM 
MgCl2, 1 mM CaCl2, 0.1% (v/v) Triton X-100].
Radioactive in vitro AMPylation (Fig. 2c) reactions were set up in a final volume of 
37.5 µl containing 1 µM of ATP hydrolysis-deficient mutant BiP protein (BiPT229A) 32, 
0.1 µM wildtype or mutant FICD proteins, 40 µM ATP, and 0.023 MBq α-32P-ATP 
(EasyTide; Perkin Elmer). The reactions were started by addition of the nucleotides 
and incubated at 25°C. After 3 and 10 minutes of incubation 15 µl were removed from 
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each reaction, respectively, supplemented with 5 µl SDS sample buffer, heated for 5 
minutes at 75°C and loaded on a SDS-PAGE gel. Gels were stained with Coomassie 
and the radioactive signals were detected with a Typhoon Trio imager (GE Healthcare) 
upon overnight exposure of the dried gels to a storage phosphor screen.
For radioactive de-AMPylation experiments (Fig. 2a) BiP was first AMPylated in vitro 
with α-32P-ATP and then re-purified. Therefore, 6 µg of purified BiP was pre-
incubated with 15 µM ATP in a final volume of 20 µl in AMPylation buffer for one 
minute at 25°C before 1.85 MBq α-32P-ATP and 2 µg FICDE234G was added. The 
mixture was incubated for 10 minutes at 25°C and another 12 µg of BiP was added. 
After further incubation for 50 minutes the reaction was diluted with 200 µl of high-
salt AMPylation buffer [25 mM HEPES-KOH pH 7.4, 500 mM KCl, 4 mM MgCl2, 1 
mM CaCl2, 0.1% (v/v) Triton X-100] and 1 mM ATP was added. BiP was then bound 
to 20 µl Ni-NTA agarose beads for 30 minutes at 20°C. The beads were washed with 
500 µl high-salt AMPylation buffer containing 1 mM ATP and three times with high-
salt AMPylation buffer. Bound proteins were eluted in 100 µl AMPylation buffer 
containing 400 mM imidazole (pH 7.4) for 30 minutes at 20°C. The eluate was split in 
two fractions of 50 µl and each fraction was passed through a Sephadex G-50 
MicroSpin column (illustra AutoSeq G-50; GE Healthcare) equilibrated with 
AMPylation buffer, and the recovered proteins were frozen in aliquots until the de-
AMPylation experiment. The de-AMPylation reactions were carried out at 23°C in a 
final volume of 15 µl in AMPylation buffer containing 1.3 µg non-radioactive 
AMPylated wildtype BiP supplemented with trace amounts of radiolabelled 
AMPylated BiP (≈ 0.1 µg). The reactions were started at different time points by 
addition of 0.13 µg wildtype or mutant FICD. At the end of the experiment 5 µl SDS 
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sample buffer were added to each reaction, proteins were denatured for 5 minutes at 
75°C, and 15 µl of each sample were applied to SDS-PAGE. After separation, the 
proteins were stained with Coomassie to confirm equal loading and radioactive signals 
were detected by autoradiography as described above.
The non-radioactive de-AMPylation reactions shown in Fig. 3d contained 1 µg/µl 
purified AMPylated wildtype BiP, 0.1 µg/µl wildtype or mutant FICD, and were 
incubated for 90 minutes at 30°C in a final volume of 25 µl in presence of 3 mM ATP. 
Afterwards, each reaction was divided in two samples, one of which was treated for 10 
minutes with 0.06 µg/µl SubA protease at 25°C, whereas the other remained 
untreated. The samples were then supplemented with native sample buffer and 
analysed immediately by native-PAGE and Coomassie staining (see below). The de-
AMPylation reactions shown in Fig. 3e were performed in HKM buffer and contained 
1 µg/µl purified AMPylated or unmodified wildtype BiP and were incubated without 
or with 0.05 µg/µl wildtype FICD for 30 minutes at 30°C in absence of ATP (to allow 
re-formation of BiP oligomers) before analysis by native-PAGE.
The reactions shown in Fig. 2b contained 3 µg/µl protein from lysates of untreated 
wildtype CHO-K1 cells or cells treated for 3 hours with CHX, and 0.15 µg/µl purified 
wildtype or mutant FICD (see above). The reactions were started by addition of 
purified FICD and incubated at 30°C. After 15 minutes, the reactions were diluted 
1:10 in IEF lysis buffer and analysed by IEF (see below).





For mass spectrometry analysis purified in vitro AMPylated or unmodified wildtype 
BiP (Chinese hamster) at 16 µM was incubated with 0.8 µM wildtype FICD or 
catalytically inactive mutant FICDH363A for 3 hours at 30°C. Afterwards, the proteins 
were denatured with SDS sample buffer, heated for 5 minutes at 75°C, and separated 
by SDS-PAGE. The gels were stained with Coomassie, destained, and the bands at 75 









Ion pair chromatography (IPC)
To detect the leaving group of the FICD-mediated de-AMPylation reaction, reversed-
phase IPC was performed (Fig. 3c). Purified in vitro AMPylated or unmodified BiP 
proteins at 65 µM were exposed to wildtype FICD or mutant FICDH363A proteins at 6.5 
µM in HKM buffer in a final volume of 30 µl for 2 hours at 30°C. At the end of the 
incubation time the reactions were stopped by addition of 10 µl of 4 M perchloric acid 
(PCA). As a negative control AMPylated BiP was incubated in parallel for 2 hours 
without enzyme and FICD was added directly before mixing with PCA. After 
incubation for 5 minutes on ice the samples were centrifuged at 21,000 g for 2 minutes 
at 4°C and 32 µl of the supernatants were mixed with 20 µl of 2 M potassium 
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hydroxide (KOH). The pH of the samples was neutralized, the precipitates were 
sedimented by centrifugation for 15 minutes at 21,000 g at 4°C, and the cleared 
supernatant were equilibrated to room temperature before analysis by IPC. For that, 20 
µl of each sample were injected onto a Poroshell 120 EC-C18 HPLC column (3 x 150 
mm, 2.7 µm; Agilent Technologies) connected to a UHPLC Guard column (Agilent 
Technologies). Buffers A [H2O + 10 mM tetrabutylammonium hydroxide (TBAH) + 
10 mM potassium dihydrogen phosphate (KH2PO4)] and B [methanol (CH3OH) + 10 
mM TBAH] were used as a mobile phase. The runs were performed at a constant flow 
rate of 0.4 ml/min at room temperature using the following gradient: 5% to 50% B in 
25 minutes, hold for 2 minutes at 50% B, ramp to 95% B in 0.1 minute, hold for 7 
minutes, 95% to 5% B in 1 minute, hold for 5 minutes at 5% B (re-equlibration to 
basal). Nucleotide absorbance traces at 254 nm (A254 nm) were recorded and plotted 
against elution time. A nucleotide standard was applied in each experiment to 
determine the retention times of ATP, ADP and AMP. 
Coupled AMPylation/de-AMPylation reactions (Fig. 3d and Supplementary Fig. 2) 
contained 20 µM ATP hydrolysis-deficient BiPT229A, 2 µM wildtype FICD, 2 µM 
FICDE234G, and 2 mM ATP in HKM buffer as indicated and were incubated for 3 hours 
at 30°C before deproteination and HPLC analysis as described above. 
Native polyacrylamide gel electrophoresis (native-PAGE)
Non-denaturing native-PAGE was performed as described 6. Briefly, Tris-glycine 
polyacrylamide gels (4.5% stacking gel and a 7.5% separation gel) were used to 
separate purified proteins or proteins from mammalian cell lysates to detect BiP 
oligomers. The separation was performed in running buffer (25 mM Tris, 192 mM 
glycine, pH ~8.8) at 120 V for 2 hours. Afterwards, the proteins were visualized by 
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staining with InstantBlue Coomassie solution (expedeon) or transferred to a 
polyvinylidene difluoride (PVDF) membrane in blotting buffer (48 mM Tris, 39 mM 
glycine; pH ~9.2) supplemented with 0.04 (w/v) SDS for 16 hours at 30 V for 
immunodetection. The membrane was washed for 20 minutes in blotting buffer 
(without SDS) supplemented with 20% (v/v) methanol before blocking. Seven µg of 
purified BiP protein was loaded per lane to detect purified BiP proteins by Coomassie 
staining and volumes of lysates corresponding to 30 µg of total protein were loaded 
per lane to detect endogenous BiP from CHO-K1 cell lysates by immunoblotting.
Immunoblot analysis
After separation by SDS-PAGE or native-PAGE (see above) the proteins were 
transferred onto PVDF membranes. The membranes were blocked with 5% (w/v) 
dried skimmed milk in TBS (25 mM Tris-HCl pH 7.5, 150 mM NaCl) and incubated 
with primary antibodies followed by IRDye fluorescently labeled secondary antibodies 
(LiCor). The membranes were scanned with an Odyssey near-infrared imager (LiCor). 
Primary antibodies and antisera against hamster BiP [chicken anti-BiP; 33], eIF2α
[mouse anti-eIF2α; 34], and FICD [chicken anti-FICD 12] were used.
Isoelectric focusing (IEF)
Analysis of lysates from mammalian cells by IEF was performed as described 
previously 12. Cells were grown in 10 cm dishes to approximately 90% confluence and 
treated with cycloheximide for 3 hours. Afterwards, the cells were washed with ice-
cold TBS, resuspended in 1 ml TBS, sedimented by centrifugation, and lysed in 30 x 
its packed cell pellet volume of IEF lysis buffer [8.8 M urea, 5% (w/v) CHAPS, 1 µM 
sodium pyrophosphate, 2 mM imidodiphosphate, 50 mM DTT, 2% (v/v) Pharmalyte] 
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at room temperature for 5 minutes. The lysates were centrifuged at 21,000 g for 10 
minutes at room temperature and the resulting supernatants were centrifuged again for 
60 minutes. The cleared lysates were passed over a Sephadex G-50 MicroSpin 
columns equilibrated with IEF sample buffer [8 M urea, 5% (w/v) CHAPS, 50 mM 
DTT, 2% (v/v) Pharmalyte (pH 4.5-5.4; GE Healthcare)], and 15 µl loaded on a 
3.75% polyacrylamide gel containing 8.8 M urea, 1.25% (w/v) CHAPS, and 5% (v/v) 
Pharmalyte. The wells were overlaid with 0.5 M urea and 2% (v/v) Pharmalyte 
solution before the run. The anode buffer was 10 mM glutamic acid and the cathode 
buffer was 50 mM histidine. The run was performed as follows: 100 V for 10 minutes, 
250 V for 1 hour, 300 V for 1 hour, 500 V for 30 minutes. The proteins were then 
transferred to a nitrocellulose membrane for 3 hours at 300 mA in blotting buffer [25 
mM Tris-HCl pH 9.2, 190 mM glycine, 0.01% (w/v) SDS, 10% (v/v) methanol] and 
BiP was detected as described above.
Data availability 
The authors declare that the data supporting the findings of this study are available 
within the paper and its supplementary information files. Source data for Fig. 6 and 
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Supplementary Figure 1 
AMPylation with ATP-FAM generates BiP specifically labeled on its substrate binding domain 
(a) SDS-PAGE gel of AMPylated BiP incubated without or with SubA protease. BiP was AMPylated in vitro with FICDE234G in presence 
of a fluorescently labeled ATP derivative (ATP-FAM) and the resulting AMPylated BiP, with a fluorescent AMP attached (BiPT518-AMP-
FAM) was re-purified (as in Fig. 2d). After prolonged treatment without or with SubA (4 hours at 30°C) the samples were denatured and 
applied to SDS-PAGE. The fluorescence signals of the fluorophore in the gel were detected (excitation: 488 nm, emission: 526 nm; 
upper panel) and the proteins were visualized by staining with Coomassie (CBB; lower panel). Uncleaved full-length BiPT518-AMP-FAM 
(FL), the nucleotide binding domain (NBD), the substrate binding domain (SBD), FICD, and SubA are indicated.  
(b) Time-dependent plot of fluorescence polarization (FP) of BiP AMPylated with FAM-labeled AMP (BiPT518-AMP-FAM, from the sample 
shown in “a” above) after incubation without (black line) or with wildtype FICD protein (red line). The decrease in the FP signal reflects 
release of the fluorophore from BiP. 





Supplementary Figure 2 
Absorbance spectra of ion pair chromatography elution profiles 
 
 
(a) 3D absorbance plots of the nucleotide standard (upper panel) and the ‘BiP-AMP + FICD’ de-AMPylation sample (lower panel) 
shown in Fig. 3c (grey and red traces therein). The elution profiles between 6 and 13 minutes are shown. Note that the absorbance 
characteristics of the AMP standard and the de-AMPylation product (both eluting at ~11.1 minutes) are qualitatively indistinguishable 
with an absorbance maximum at ~260 nm (arrows). 





Supplementary Figure 3 
Analysis of FICD overexpression in cells 
 
 
(a) FICD immunoblot of FICD-deficient (-/-) CHO-K1 cells transfected with plasmids encoding the indicated FICD derivatives. The eIF2α 
below serves as a loading control. Note the higher protein levels of the weaker AMPylation active/de-AMPylation defective 
FICDE234V/L/Q/K mutants compared to the AMPylation hyperactive FICDE234G. 
(b) Flow cytometry source data from a representative experiment (one of three) used to generate the plot in Fig. 6b. 





Supplementary Figure 4 
Analysis of FICD overexpression by flow cytometry and native-PAGE 
 
 
(a) Flow cytometry source data from one of three independent repeats plotted in Fig. 6c. 
(b) Immunoblot of endogenous BiP from wildtype and FICD-deficient (-/-) CHO-K1 cells resolved by native-PAGE. The cells were co-
transfected with the indicated pairs of plasmids as in Fig. 6c and allowed to grow for 36 hours. The AMPylated ‘B’ form of BiP is 
indicated (as are the other major species, see Fig. 1 legend). Immunoblots of the same samples resolved by SDS-PAGE report on 
FICD, total BiP and total eIF2α (which also serves as a loading control). Data representative of two independent experiments are 
shown. 
Note the absence of AMPylated BiP (‘B’ form) in cells co-transfected with wildtype FICD and the de-AMPylation defective/AMPylation 
active FICDE234G. 





Supplementary Figure 5 
Wildtype and FICD-deficient (-/-) cells respond indistinguishably to unfolded protein stress in the ER 
(a) Flow cytometry analysis of wildtype and FICD-deficient (-/-) CHO-K1 CHOP::GFP UPR reporter cells treated with the UPR-inducing 
compounds, tunicamycin (2.5 µg/ml) or thapsigargin (0.5 µM), for 16 hours before analysis. Note the equal accumulation of 
CHOP::GFP-positive cells in tunicamycin- or thapsigargin-treated wildtype and FICD-/- cells. 
(b) Plot of the median values ± SD of the GFP fluorescent signal of the samples described in “a” from three independent experiments 
(fold change relative to untreated wildtype cells). 
(c) Flow cytometry analysis of wildtype and FICD-deficient (-/-) CHO-K1 CHOP::GFP UPR reporter cells transiently transfected with 
plasmids encoding the Cas9 nuclease and single guide RNAs targeting hamster BiP. Note the similar levels of UPR signaling in 
wildtype and FICD-/- cells. 
(d) Plot of the median values ± SD of the CHOP::GFP fluorescent signal in the transfected subpopulation of the cells shown in “c” from 
three independent experiments. Transfected cells were identified by co-expression of a mCherry marker (not shown) carried by the 




FICD (wildtype vs. mutants) overexpression-dependent induction of unfolded protein 
response signalling was analyzed by transient transfection of wildtype and FICD-/- 
CHOP::GFP CHO-K1 UPR reporter cell lines with plasmid DNA encoding the FICD 
protein and mCherry as a transfection marker, using Lipofectamine LTX as described 
previously 1; 2 µg DNA were used in Fig. 6b and 1 µg each plasmid were used in Fig. 
6c. Thirty-six hours after transfection cells were washed with PBS and collected in 
PBS containing 4 mM EDTA, and single cell fluorescent signals (20,000/sample) 
were analyzed by dual-channel flow cytometry with an LSRFortessa cell analyzer 
(BD Biosciences). GFP and mCherry fluorescence was detected with excitation laser 
488 nm, filter 530/30, and excitation laser 561, filter 610/20, respectively. Data were 
processed using FlowJo and median reporter (in Q1 and Q2 in Fig. 6b & c) analysis 
was performed using Prism. 
The sensitivity to UPR induction in wildtype and FICD-deficient CHO-K1 
CHOP::GFP UPR reporter cell lines was analyzed by treating cells with UPR-
inducing compounds, tunicamycin or thapsigargin, for 16 hours before analysis, or 
transient transfection with 2 µg plasmid DNA encoding the Cas9 nuclease and single 
guide RNAs targeting hamster BiP. The two single guide RNA sequences (plasmids 
UK1857 and UK1858; Supplementary Table 1) for targeting the second exon of 
Cricetulus griseus (Chinese hamster) BiP (HSPA5) were selected from the CRISPy 
database [URL: http://staff.biosustain.dtu.dk/laeb/crispy/, 2] and duplex DNA 
oligonucleotides of the sequences were inserted into the pSpCas9(BB)-2A-
mCherry_V2 plasmid (plasmid UK1610; Supplementary Table 1) as described 3. Four 
days after transfection cells were analysed by flow cytometry as described above. 
Production	of	VSV-G	retroviral	virus	in	HEK293T	cells	and	infection	of	CHO-K1	cells	
The effect of expression of de-AMPylation-defective/AMPylation-active FICDE234G 
on mammalian cell fitness was analyzed by colony outgrowth of wildtype and FICD-/- 
CHO-K1 cell lines targeted with puromycin-resistant retrovirus expressing FICDE234G. 
For that HEK293T cells were split onto 6 cm dishes 24 hours prior to co-transfection 
of pBABE Puro plasmids 4 encoding FICDE234G or inactive FICDE234G-H363A (plasmids 
UK1852 and UK1853, respectively; Supplementary Table 1) with VSV-G retroviral 
packaging vectors, using TransIT-293 Transfection Reagent (Mirus) according to the 
manufacturer’s instructions. Sixteen hours after transfection, medium was changed to 
medium supplemented with 1% BSA (Sigma). Retroviral infections were performed 
following a 24 hours incubation by diluting 0.45 µm filter-sterilized cell culture 
supernatants at a 1:2 ratio into CHO-K1 cells medium supplemented with 10 µg/ml 
polybrene (4 ml final volume) and adding this preparation to wildtype or FICD-/- 
CHO-K1 cells (3 x 105 cells seeded onto 6 cm dishes 24 hour prior to infection). 
Infections proceeded for 8 hours, after which viral supernatant was replaced with 
fresh medium. Forty-eight hours later cells were split into medium supplemented with 
6 µg/ml puromycin, and 24 hours afterwards this was changed to medium 
supplemented with 8 µg/ml puromycin. The medium was changed every third day 
until puromycin-resistant colonies were visible. Colonies remaining on the dishes 9 
days after infection were visualized by crystal violet stain and counted. 
Fluorescence	polarization	assay	
The probe to measure the kinetics of FICD-mediated de-AMPylation by fluorescence 
polarization (FP) assays was generated as follows: Purified active FICDE234G at 10 
µM was pre-incubated with 2 mM 5-FAM-labeled N6-(6-Amino)hexyl-adenosine-5’-
triphosphate (ATP-FAM; Jena Bioscience) in HKMG buffer for 5 minutes at 25°C 
before BiPV461F protein at 10 µM was added to yield a final reaction volume of 50 µl. 
The substrate binding- and oligomerisation-deficient BiPV461F mutant was used to 
avoid effects caused by BiP oligomerisation on fluorescence polarization 
measurements. The AMPylation reaction was allowed to proceed for 2 hours at 25°C. 
BiP protein was then bound to Ni-NTA agarose beads in presence of 0.01% (v/v) 
Triton X-100 and after several wash steps in the same buffer proteins were eluted in 
HKMG containing 250 mM imidazole. The eluted proteins were passed over a 
desalting column equilibrated in HKMG and aliquots were frozen in liquid nitrogen 
and stored at -80°C. 
To confirm covalent modification of BiPV461F with AMP-FAM the eluted proteins 
were incubated without or with 60 ng/µl SubA protease for an elongated period of 
time (4 hours) in AMPylation buffer at 30˚C. The proteins were then denatured in 
SDS sample buffer for 5 minutes at 75°C and separated by SDS-PAGE. The 
fluorescence signals were detected with a Typhoon Trio imager (GE Healthcare; λex = 
488 nm, λem = 526 nm) before the gels were stained with Coomassie to visualize 
proteins (Supplementary Fig. 1a). To compare de-AMPylation of full-length BiP and 
the isolated substrate binding domain (Fig. 4a) AMP-FAM modified BiPV461F 
(BiPV461F-AMP-FAM) was first cleaved for 4 hours with SubA and then exposed to 0.75 
µM wildtype FICD protein for the indicated periods of time before denaturation and 
SDS-PAGE analysis as described above.  
FP assays were performed in 384 well polysterene microplates (black, flat bottom, 
µCLAER; greiner bio-one) by monitoring fluorescence polarization of FAM (λex = 
485 nm, λem = 535 nm) using a TECAN plate reader (Infinite F500, G-factor ≈ 0.82). 
The reactions were performed in a final sample volume of 30 µl and started by 
addition of either enzyme or substrate. To measure enzyme kinetics at excess of 
substrate the reactions contained the same concentration of enzyme (wildtype FICD 
protein without the GST-tag; [E] = 0.75 µM) and trace amounts of fluorescent 
BiPV461F-AMP-FAM probe (17 nM) and were supplemented with increasing 
concentrations of non-fluorescent BiPV461F-AMP ([S] = 2 µM to 50 µM), assuming that 
both were de-AMPylated with similar efficiency (Fig. 4c). All reactions were 
performed at 30°C in AMPylation buffer. Substrate-only controls were included in 
each experiment for correction of the test sample values. The linear initial rates in 
millipolarization units per second (mP/sec) were converted to reaction velocity 
(µM/sec) using Equation 1, where ΔFP/Δt is the initial rate, ΔFPc is the absolute 
change in FP signal at completion of the reaction, and [S] is the substrate 
concentration.  
 
Equation 1:  ν0= ((ΔFP/Δt)/ΔFPc)*[S] 
 
To calculate the Km for FICD-mediated de-AMPylation of BiPV461F-AMP the 
Michaelis-Menten equation 5 was fitted to a plot of the initial reaction velocities 
against the substrate concentrations from three independent experiments (n = 3). Data 
analysis was performed using Prism 6.0e (GraphPad Software, Inc.). 
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